Ionis Pharma: Will Its Expansion of Cardiology Portfolio With Next-Generation ASO Therapies Become The Next BIG THING?

Ionis Pharmaceuticals has demonstrated notable progress and robust performance in its third quarter of 2025, driven by advancements in its drug pipeline and strategic launches. The company, specializing in RNA-targeted therapies, is focused on treating serious diseases in domains such as neurology and cardiometabolic areas. Ionis has successfully commenced its first independent launch of TRYNGOLZA, the sole FDA-approved treatment for familial chylomicronemia syndrome (FCS), with encouraging market performance, leading to an increased revenue forecast for 2025. The product’s recent approval in Europe is set to potentially expand its market footprint. Another significant milestone is the approval and launch of DAWNZERA for hereditary angioedema (HAE), with early adoption indicating promising demand. The company reported positive results from two significant programs within its wholly-owned pipeline. The success of Olezarsen in treating severe hypertriglyceridemia (sHTG) marked by significant reductions in triglycerides and acute pancreatitis positions it for upcoming independent launches.